Advertisement
Journal Home
Search for

Volume 18, Issue 4, Pages 379-384 (December 2009)


View previous. 10 of 15 View next.

Impact of total retrieved lymph nodes on staging and survival of patients with gastric cancer invading the subserosa

Caigang Liu, Yang Lu, Zhu Jun, Ruishan Zhang, Fan Yao, Ping LuCorresponding Author Informationemail address, Feng Jin, Hua Li, Huimian Xu, Shubao Wang, Junqing Chen

Accepted 18 September 2008.

Abstract 

Purpose

To investigate the impact of total retrieved lymph nodes (tLNs) on staging and survival in patients with pT2b gastric cancer according to the nodal status.

Methods

Clinicopathological characteristics and prognostic outcomes of 392 patients with pT2b gastric cancer between 1980 and 2005 were retrospectively investigated based on the nodal status.

Results

The number of metastatic lymph nodes (mLNs) was highly correlated with the number of tLNs (P<0.001). The overall 5-year and 10-year survival rates were 39.0% (153/392) and 17.9% (70/392), respectively. The survival rates in patients with pN0 cancers did not differ significantly from that in patients with pN1 cancer when the tLNs were 25 or less. However, the survival rate in patients with N0 cancers was significantly greater than that in patients with pN1 cancers when the tLNs were more than 25 (64.3% vs. 36.9%, χ2=4.339, P=0.037). Moreover, both 5- and 10-year survival rates differed significantly among patients with pN1, pN2 and pN3 gastric cancer regardless of tLNs. Multivariate analysis revealed that age, tumor focus number, tumor location, and mLN, but not tLNs, were independent prognostic predictors in patients with pT2b gastric cancer.

Conclusions

To improve the accuracy of staging, no less than 15 tLNs should be pathologically examined in patients with pN1–3, and 25 tLNs for the patients with N0. More tLNs may not be associated with a better prognosis in pT2b disease because the extent of lymph node dissection is pre-defined for the operation.

Department of Oncology, First Affiliated Hospital of China Medical University, Shenyang, China

Corresponding Author InformationCorrespondence to: Department of Surgical Oncology, First Affiliated Hospital of China Medial University, Heping, Shenyang, Liaoning Province 110001, China. Tel.: +86 24 13002481019; fax: +86 24 22834060.

PII: S0960-7404(08)00088-1

doi:10.1016/j.suronc.2008.09.002


View previous. 10 of 15 View next.

Advertisement